The Rights Issue carried out by Peptonic was secured by subscription undertakings amounting to approximately 31.5 per cent and guarantee commitments amounting to approximately 35.6 per cent, corresponding to a total of approximately 67.1 per cent. The guarantors were entitled to compensation of fifteen (15) per cent of the guaranteed amount in cash or twenty (20) per cent of the guaranteed amount in units, on the same terms as the units in the Rights Issue. Against this background, and pursuant to the authorization granted by the annual general meeting of the Company held on 26 June 2025, the Board of Directors has today resolved on the Compensation Issue, which comprises a total of 100,557,800 shares and 100,557,800 warrants of series TO6. The subscription price amounts to SEK 0.16 per unit, corresponding to the subscription price in the Rights Issue. Each unit consists of one hundred (100) newly issued shares and one hundred (100) free warrants of series TO6.

The deviation from the shareholders' preferential rights in the Compensation Issue is motivated by the Company's contractual obligations towards the guarantors. The Board of Directors considers it beneficial for the Company's financial position to utilize the option of settling the guarantee compensation in the form of units instead of cash, as this has a positive effect on the Company's liquidity. Payment in the Compensation Issue is made by way of set-off against the guarantors' claims on the Company for guarantee compensation. The subscription price in the Compensation Issue was negotiated on an arm's length basis in connection with the procurement of the guarantee commitments, following an analysis of customary market factors. Accordingly, the Board of Directors assesses that the subscription price is market-based.

Shares, share capital and dilution

Through the Compensation Issue, and following registration of the Rights Issue, the total number of shares in the Company increases by 100,557,800 shares, from 20,624,009,514 shares to 20,724,567,314 shares, corresponding to a dilution of approximately 0.5 per cent of the total number of shares and votes in the Company. The share capital increases by approximately SEK 10,055.78, from approximately SEK 2,062,400.95 to approximately SEK 2,072,456.73. In the event that all warrants of series TO6 issued within the framework of the Compensation Issue are exercised, the number of shares in the Company will increase by a further 100,557,800 shares, from 20,724,567,314 shares to 20,825,125,114 shares, corresponding to a dilution of approximately 0.5 per cent of the total number of shares and votes in the Company. Furthermore, the share capital will increase by an additional approximately SEK 10,055.78, from approximately SEK 2,072,456.73 to approximately SEK 2,082,512.51.

For more information contact:

Anna Linton, CEO Peptonic Medical AB

Email: [email protected]

Phone: +46 70-244 92 07

About Peptonic Medical AB

Peptonic Medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development, and actual outcomes may differ materially from the statements set forth in the forward-looking information.